Comprehensive Guide to Stimulant Dose Conversion
A stimulant dose conversion calculator can help clinicians, students, and informed patients estimate how one ADHD stimulant dose might compare to another. Because stimulant medications vary in molecular composition, bioavailability, duration of action, and release technology, direct milligram-to-milligram comparisons are often misleading. Conversion frameworks create a common reference unit so that transitions can be planned more safely and discussed more clearly with a prescribing professional.
This page combines a practical conversion tool with an in-depth educational reference. The purpose is to improve understanding of stimulant equivalency logic and highlight why all conversion outputs must be interpreted in context. In real treatment settings, medication switches are influenced by age, cardiovascular history, sleep patterns, appetite impact, anxiety vulnerability, prior adverse reactions, and goals for symptom coverage across school, work, or evening routines.
Why stimulant conversion matters
Stimulant conversion is commonly needed when insurance formularies change, side effects emerge, pharmacy shortages occur, or daily schedules demand a different duration profile. Patients may also need transitions between immediate-release and extended-release products to improve adherence or reduce midday dosing burden. A conversion estimate gives a starting point, but the final prescribed dose should still be individualized and reassessed after initiation.
Even within the same class, products are not interchangeable in effect timing. Two doses with similar total daily stimulant exposure may feel very different due to onset speed, peak intensity, and tail duration. For example, a patient with afternoon rebound symptoms may do better with a long-acting profile despite a numerically similar equivalent dose. Conversely, patients sensitive to appetite suppression or insomnia may benefit from shorter-acting coverage and lower evening exposure.
Medication groups included in this calculator
| Medication | Typical Class | Relative Stimulant Unit (RSU) per mg | Notes |
|---|---|---|---|
| Dextroamphetamine IR | Amphetamine-based | 1.00 | Reference anchor in this model |
| Mixed Amphetamine Salts IR/XR | Amphetamine-based | 0.75 | Approximate blended amphetamine potency |
| Lisdexamfetamine | Amphetamine prodrug | 0.30 | Prodrug conversion changes mg relationship |
| Methylphenidate IR/ER | Methylphenidate-based | 0.50 | Often less potent mg-for-mg vs amphetamine class |
| Dexmethylphenidate IR/XR | Methylphenidate-based | 1.00 | Active d-isomer; higher potency per mg than racemic methylphenidate |
How the calculator works
The tool uses a two-step method: first, it converts the source dose to a neutral potency unit; second, it converts that unit to the target drug. The formula is:
Target dose (mg) = Source dose × Source RSU ÷ Target RSU
After calculation, the result can be rounded to practical dose increments used in real prescribing workflows. This improves usability but introduces additional approximation. A good clinical approach is to treat the rounded output as an upper boundary for consideration and then decide whether a lower starting dose is safer.
Key limitations you should always remember
Any stimulant conversion tool, including this one, has important limitations. It cannot predict personal sensitivity, symptom response curve, comorbid anxiety, or interaction risk with other medications. It does not account for release mechanisms such as biphasic beads, osmotic pump systems, or delayed-release profiles that can dramatically alter symptom timing. It also cannot replace blood pressure and heart rate monitoring after dose changes.
The biggest practical limitation is that symptom control is multidimensional. A dose that improves focus may worsen mood lability or sleep. Another dose may reduce impulsivity but not sustain working memory through late afternoon. Therefore, dose conversion should be viewed as an initial map, not a final destination. Titration and follow-up remain essential.
Clinical context that can change final dosing decisions
Prescribers often adjust away from strict equivalence when specific risk factors are present. Younger patients may require conservative starts with slower titration steps. Adults with hypertension, tachycardia, panic symptoms, or insomnia risk may also be started below estimated equivalent values. In patients with severe morning impairment, clinicians may prioritize faster onset even if nominal equivalent potency is unchanged.
Another common scenario is partial response with side effects at higher doses. In these cases, the best strategy may involve changing class rather than escalating within class. A patient not tolerating one amphetamine product might do better on methylphenidate-based therapy, and vice versa. Conversion calculators help estimate a bridge dose but cannot determine which mechanism will be better tolerated.
Immediate-release vs extended-release considerations
Total daily milligrams are only one part of stimulant therapy. Immediate-release products generally peak sooner and clear earlier, which can be useful for targeted symptom windows and flexible timing. Extended-release products support adherence and can provide smoother daytime coverage but may last into evening hours and affect appetite or sleep. When converting, clinicians may split equivalent totals differently based on daily routine.
For example, a mathematically similar daily dose could be prescribed as one morning ER dose, two IR doses, or ER plus afternoon IR booster. Each plan may generate a different lived experience despite similar total exposure. This is why post-conversion monitoring is critical during the first one to three weeks.
Monitoring after a stimulant switch
After changing stimulant medications, common monitoring domains include blood pressure, resting heart rate, appetite, weight trajectory, sleep latency, irritability, anxiety symptoms, and functional outcomes at school or work. A structured symptom log can make follow-up visits more objective. Patients who track timing of benefit and timing of side effects often help clinicians optimize regimen design faster.
Warning signs that need prompt medical review include chest pain, shortness of breath, severe insomnia, marked mood destabilization, persistent tachycardia, or unusual behavioral changes. These are not expected routine adjustment effects and should not be managed by self-directed dose experiments.
Practical tips for safer conversion discussions
Bring a complete medication list including caffeine intake, nicotine use, over-the-counter stimulants, and supplements. Document your current schedule, symptom priorities, and the specific problem driving the switch, such as morning delay, afternoon crash, or appetite suppression. Ask your clinician about a starting dose, titration intervals, and a clear follow-up timeline. Confirm whether weekend dosing should differ from weekday dosing based on goals and tolerability.
If there is a pharmacy shortage, ask about equivalent alternatives in both IR and ER forms. Availability can change by region and month, and flexibility with formulation can reduce treatment interruption. Always verify capsule strength options because real-world packaging can affect rounding decisions.
Frequently asked questions
Is this stimulant conversion calculator suitable for self-prescribing?
No. It is strictly educational. Dose changes should be made only under medical supervision.
Why are equivalent numbers sometimes lower than expected?
Different medications have different pharmacology and delivery characteristics. Equivalent total potency may not require a similar mg number.
Can children and adults use the same conversion output?
Not automatically. Age, body size, metabolism, and side-effect profile often justify different starting strategies.
Do generic and brand products convert identically?
Potency targets are comparable, but release profiles and patient experience may vary slightly across products.
What is the best use of a conversion estimate?
Use it as a discussion starting point with a licensed clinician, then adjust based on objective response and tolerability.
Final perspective
A stimulant dose conversion calculator is most valuable when paired with professional assessment and ongoing monitoring. It helps translate one regimen into another in a consistent, transparent way, especially during shortages, insurance changes, and therapeutic optimization. The strongest outcomes come from combining conversion math with individualized care: conservative starts when needed, deliberate titration, and timely follow-up guided by real-world function and safety measures.